Predictive Oncology enters ATM sales agreement for up to $3.7M of common stock with H.C. Wainwright

Axe Compute Inc.

Entered ATM Sales Agreement with H.C. Wainwright for up to $3,696,000 of common stock.
Shares sold through 'at the market offering'; 3.0% commission to agent.
No obligation to sell; Company may set parameters including minimum price.
Registration statement on Form S-3 to be filed; sales subject to effectiveness.
Stock trades on NASDAQ Capital Market under symbol POAI.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Axe Compute Inc. entered into Sales Agreement with H.C. Wainwright & Co., LLC valued at $3,696,000 (effective 2024-05-03).

Action: entry
Agreement: atm program
Counterparty: H.C. Wainwright & Co., LLC
Value: $3,696,000
Effective: 2024-05-03

Exact text from the filing

On May 3, 2024, Predictive Oncology Inc., a Delaware corporation, (the “Company”), entered into an ATM Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”), as sales agent to sell shares of the Company’s common stock, par value $0.01 per share, from time to time, through an “at the market offering” program pursuant to which Wainwright will act as sales agent.

View on SEC.gov

Browse all material agreements →

Axe Compute Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002541

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.